On March 11, China Meheco Group Co.Ltd(600056) again raised the limit by one word. Stimulated by the news of signing a contract with Pfizer, 6 Luzhou Laojiao Co.Ltd(000568) day 6 board rose by nearly 90%.
That night, the company issued a change announcement, saying that Pfizer covid-19 virus treatment drugs have not yet entered the national medical insurance and covid-19 pneumonia diagnosis and treatment plan, and there is great uncertainty in the final use and sales affected by epidemic prevention and control and other factors, and it is expected that the scale of relevant business accounts for a small proportion of the company’s overall business volume, It has no significant impact on the company’s recent operating performance
8 day 6 board continued to rise sharply
On March 11, China Meheco Group Co.Ltd(600056) opened again and closed at 20.93 yuan per share, up 9.98%. The turnover was 980 million yuan, the turnover rate was 4.8%, and the latest market value was 22.36 billion yuan. As of the close, there were still as many as 245000 hands on the daily limit.
Looking back on the recent trend, since March 2, China Meheco Group Co.Ltd(600056) share price has soared all the way from 11.1 yuan, and won a total of 6 limit boards in 8 trading days, with a cumulative increase of about 89%, with a strong performance.
In terms of news, it was previously rumored in the market that China Meheco Group Co.Ltd(600056) company was communicating with a multinational pharmaceutical company on the cooperation of covid-19 virus treatment drugs. In March 10th, China Meheco Group Co.Ltd(600056) announced that it had signed an agreement with Pfizer Inc in March 9th and will be responsible for the commercial operation of Pfizer Inc COVID-19 virus treatment PAXLOVID in Chinese mainland in 2022.
China Meheco Group Co.Ltd(600056) appeared on the Dragon Tiger list due to the cumulative deviation of the closing price increase over 20% in three consecutive trading days.
According to the data, in the past three trading days, the top five business departments with the largest purchase amount bought a total of 377 million yuan, of which the business department of Yuanshen road in Orient Securities Company Limited(600958) Shanghai Pudong New Area, located in the first place, bought 124 million yuan; The top five business departments with the largest sales amount sold a total of 329 million yuan, of which the special account of Shanghai Stock connect located in selling No. 1 sold a total of 779182 million yuanP align = “center” Image Source: company announcement
company: the scale of related business accounts for a relatively small proportion
On the evening of March 11, China Meheco Group Co.Ltd(600056) announced that after self inspection, the company’s current production and operation activities are normal and there are no major events affecting the abnormal fluctuation of the company’s stock trading price.
In view of the operation of Pfizer covid-19 therapeutic drugs in the Chinese market, the announcement said that the product is a prescription drug and has not yet entered the national medical insurance and covid-19 pneumonia diagnosis and treatment plan. The final use and sales are affected by epidemic prevention and control and other factors, there is great uncertainty, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, It has no significant impact on the company’s recent operating performance.
The company also said that recently, the company’s share price fluctuated greatly. Please pay attention to the trading risks in the secondary market, make rational decisions and invest prudently.
There are differences in the future
Although the company has continuously prompted risks, some investors in the stock bar are strongly optimistic about the future performance. Some investors said that at present, the China Meheco Group Co.Ltd(600056) static P / E ratio is only about 17 times, and the dynamic P / E ratio is only about 20 times. The cooperation with Pfizer may open the space for performance growth, thus driving the stock price to rise continuously.
However, some investors said that the cooperation with Pfizer has not released more specific details. Recently, the stock has increased greatly, and continued speculation will face greater risks, so it is not suitable to be blindly optimistic.
Basically, China Meheco Group Co.Ltd(600056) released a performance forecast earlier, saying that the net profit attributable to shareholders of listed companies is expected to be 300 million yuan to 700 million yuan in 2021, a year-on-year decrease of 77% to 47%.
The company said that the pre reduction of performance was mainly due to the sharp year-on-year decline in export epidemic prevention business due to changes in overseas epidemic situation.
